1 day Ago By Defense World Staff
Geode Capital Management LLC cut its position in shares of Myriad Genetics, Inc. ( NASDAQ:MYGN – Free Report ) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The institutional investor owned 2,142,869 shares of the company’s stock after selling 11,166 shares during the period. Geode Capital Management LLC owned about 2.35% of Myriad Genetics worth $29,386,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in MYGN. Jane Street Group LLC increased its holdings in Myriad Genetics by 19.4% during the third quarter.
Jane Street Group LLC now owns 121,181 shares of the company’s stock valued at $3,319,000 after buying an additional 19,684 shares during the period. Barclays PLC boosted its position in Myriad Genetics by 136.9% during the third quarter.
Barclays PLC now owns 190,243 shares of the company’s stock valued at $5,210,000 after purchasing an additional 109,931 shares in the last quarter. Franklin Resources Inc. grew its stake in Myriad Genetics by 8.
8% in the third quarter. Franklin Resources Inc. now owns 58,055 shares of the company’s stock valued at $1,457,000 after purchasing an additional 4,710 shares during the last quarter.
Nordea Investment Management AB boosted its holdings in shares of Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company’s stock valued at $4,548,000 after buying an additional 179,527 shares in the last quarter.
Finally, Inspire Investing LLC grew its position in shares of Myriad Genetics by 84.9% in the 4th quarter. Inspire Investing LLC now owns 31,373 shares of the company’s stock worth $430,000 after buying an additional 14,406 shares during the last quarter.
Institutional investors own 99.02% of the company’s stock. Analyst Upgrades and Downgrades MYGN has been the topic of several research reports.
Craig Hallum assumed coverage on Myriad Genetics in a research report on Wednesday, February 12th. They issued a “buy” rating and a $29.00 target price on the stock.
Piper Sandler raised shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $11.50 to $12.50 in a report on Wednesday, March 12th.
Stephens restated an “equal weight” rating and issued a $20.00 price target on shares of Myriad Genetics in a research report on Thursday, January 16th. Scotiabank decreased their target price on shares of Myriad Genetics from $24.
00 to $20.00 and set a “sector outperform” rating on the stock in a research report on Tuesday, April 1st. Finally, The Goldman Sachs Group reduced their target price on shares of Myriad Genetics from $18.
00 to $14.00 and set a “buy” rating on the stock in a report on Thursday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company.
Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.61. Myriad Genetics Price Performance MYGN stock opened at $7.
64 on Friday. The firm has a 50-day moving average of $10.34 and a two-hundred day moving average of $14.
55. The company has a current ratio of 1.90, a quick ratio of 1.
73 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc.
has a one year low of $7.35 and a one year high of $29.30.
The firm has a market capitalization of $704.19 million, a PE ratio of -5.88 and a beta of 1.
87. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.
09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12).
Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%.
The company had revenue of $210.60 million for the quarter, compared to analysts’ expectations of $210.35 million.
During the same period in the previous year, the firm posted ($0.12) earnings per share. On average, analysts forecast that Myriad Genetics, Inc.
will post -0.3 earnings per share for the current year. About Myriad Genetics ( Free Report ) Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. Featured Stories Five stocks we like better than Myriad Genetics Asset Allocation: The Key to a Successful Portfolio.
Are You Paying Attention to Yours? Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally High Dividend REITs: Are They an Ideal Way to Diversify? Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar How to Buy Gold Stock and Invest in Gold Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. ( NASDAQ:MYGN – Free Report ). Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.
com's FREE daily email newsletter ..
